2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
81
Colonic Neoplasms
18
Neoplasm Metastasis
17
Rectal Neoplasms
14
Neoplasms
13
Stomach Neoplasms
7
Carcinoma, Non-Small-Cell Lung
5
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Lung Neoplasms
4
Gastrointestinal Neoplasms
4
Carcinoma, Renal Cell
3
Carcinoma, Neuroendocrine
3
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Leukemia, Myeloid, Acute
2
Breast Neoplasms
2
Brain Neoplasms
2
Adenocarcinoma
2
Urinary Bladder Neoplasms
1
Unresectable Metastatic Colorectal Cancer
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Solid Tumors
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Ras-mutated Metastatic Colorectal Cancer
1
Prostatic Neoplasms
1
Interventions
Gemcitabine
5
130-nm albumin-bound paclitaxel
3
Albumin-Bound Paclitaxel
2
spartalizumab
1
canakinumab
1
Taxes
1
SLC-0111
1
IFL protocol
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metastatic Pancreatic Ductal Adenocarcinoma
×
IFL protocol
×
Clear all
NCT03331640
2022-01-11
PANTHEON
AIO-Studien-gGmbH
Phase 2
Terminated
67 enrolled